与癌症相关的凝血病和外科手术期间的考虑
Seema P Deshpande1, Reney A Henderson1, Aniruddh U Ajith2
1From the Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland.
Anesthesia and analgesia
|December 4, 2024
概括
癌症患者表现出复杂的凝血问题,增加出血和凝血的风险. 麻醉科医生必须了解这些静血系统障碍,以便在这个不断增长的患者群体中提供最佳的外科护理.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 麻醉学 麻醉学
背景情况:
- 癌症患者经常出现复杂的凝血异常,影响静血系统.
- 这些异常会增加血栓和出血并发症的风险,增加发病率和死亡率.
- 改进的癌症疗法提高了患者的生存率,导致需要外科手术的患者人数增加.
研究的目的:
- 突出麻醉科医生了解癌症相关的凝血失调的关键需求.
- 为了解这些异常的类型,病理生理学和临床表现提供见解.
- 强调优化手术前期管理,为癌症患者进行手术.
主要方法:
- 这项研究是对有关癌症的凝血异常的当前文献的综述.
- 它综合了有关病理生理学和临床影响的信息.
- 专注于麻醉师的外科外科考虑.
主要成果:
- 与癌症相关的凝血障碍复杂且普遍存在.
- 这些疾病显著增加了外科手术期间的风险.
- 了解这些障碍对于有效的患者管理至关重要.
结论:
- 与癌症相关的凝血异常在手术环境中带来了重大挑战.
- 麻醉科医生需要对这些静血失调的综合知识.
- 优化术后护理对于改善这一患者群体的治疗结果至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
616
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
616
Disorders of Hemostasis
707
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
707
Coagulation
4.7K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
4.7K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Extrinsic and Intrinsic Pathways of Hemostasis
5.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.5K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328


